Analysis of a 1122 EGFR-mutant patient cohort revealed that multiple co-occurring oncogenic events are present in most advanced-stage EGFR-mutant lung cancers, including PIK3CA mutation [6]. This evidence concerns the gene EGFR and lung carcinoma.